Published in final edited form as:

Bioorg Med Chem. 2008 October 1; 16(19): 8959–8967. doi:10.1016/j.bmc.2008.08.047.

Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: A QSAR investigation

Yongcheng Song^a, Julian M.W. Chan^a, Zev Tovian^a, Aaron Secrest^b, Eva Nagy^b, Kilannin Krysiak^a, Kyle Bergan^a, Michael A. Parniak^b, and Eric Oldfield^{a,*}

^a Department of Chemistry, 600 South Mathews Avenue, University of Illinois at Urbana-Champaign, Urbana, IL 61801, U.S.A

^b Department of Molecular Genetics & Biochemistry, University of Pittsburgh, Pittsburgh, PA 15261, USA

Abstract

We report the results of an investigation of the inhibition of the ATP-mediated HIV-1 reverse transcriptase catalyzed phosphorolysis *in vitro* of AZT from AZT-terminated DNA primers by a series of 42 bisphosphonates. The four most active compounds possess neutral, halogen-substituted phenyl or biphenyl sidechains and have IC₅₀ values < 1 μM in excision inhibition assays. Use of two comparative molecular similarity analysis methods to analyze these inhibition results yielded a classification model with an overall accuracy of 94%, and a regression model having good accord with experiment ($q^2 = 0.63$, $r^2 = 0.91$), with the experimental activities being predicted within, on average, a factor of 2. The most active species had little or no toxicity against three human cell lines (IC₅₀^{avg} > 200 μM). These results are of general interest since they suggest that it may be possible to develop potent bisphosphonate-based AZT excision inhibitors with little cellular toxicity, opening up a new route to restoring AZT sensitivity in otherwise resistant HIV-1 strains.

Keywords

Reverse transcriptase; Nucleoside reverse transcriptase inhibitor (NRTI); Bisphosphonate; Quantitative structure activity relationship (QSAR)

1. Introduction

HIV-1 is a major cause of AIDS with ~40,000,000 individuals infected¹. The first drug approved for the clinical treatment of HIV-1 infection was 3'-azido, 3'-deoxythymidine (AZT, Retrovir[®], Retrovis[®] and Zidovudine[®]). When taken up into cells AZT is converted to AZT-triphosphate, which can then be incorporated into nascent viral DNA², resulting in a so-called "blocked DNA primer" that contains a terminal azide (-N₃) rather than an -OH group. The terminal OH → -N₃ substitution prevents DNA elongation and, consequently, viral DNA replication is terminated. However, shortly after the introduction of AZT, cases of resistance were found. This resistance originates in the phosphorolytic excision of AZT by ATP (and, to a lesser extent, PPi) catalyzed by viral reverse transcriptase^{3–5} (RT), as illustrated below:

*Corresponding author. Tel.: 217-333-3374; Fax: 217-244-0997; E-mail: eo@chad.scs.uiuc.edu.

In most cases, resistance originates from specific RT mutations called thymidine analog mutations (TAMs)^{6–10}. Specific inhibitors of AZT excision, and in principle the excision of other nucleoside reverse transcriptase inhibitors (NRTIs), could have therapeutic utility, since they might restore the activity of the NRTI against HIV-1. Optimally, such inhibitors should not reduce incorporation of an NRTI, since this would clearly antagonize their anti-retroviral activity. We demonstrate here that selective inhibitors of RT-catalyzed phosphorolytic excision of NRTIs can be identified.

While screening large libraries of compounds for activity in inhibiting AZT excision might be one approach to discovering NRTI-excision inhibitors, current assay methods are not well suited for high-throughput screening. An alternative approach might, however, be to screen smaller libraries of compounds containing hydrolytically stable analogs of diphosphate or triphosphate, which could block AZT (or PPI) binding to RT. Conceptually, the simplest analogs of PPI to consider are the so-called bisphosphonate class of drugs (used to treat bone resorption diseases) in which the central, bridging oxygen atom is replaced by a methylene (2) or substituted methylene group, such as 3, 4:

and in previous work¹¹ we reported that the bisphosphonate 3 had some activity in this context. More recently, Cruchaga et al.¹² have followed up on this work, finding that the bisphosphonate pamidronate (4) competitively inhibited the phosphorolytic activity of RT, and synergistically inhibited HIV-1 RT in combination with AZT-triphosphate, in the presence of either ATP or PPI. And in more recent work, this group found similar results with the anti-viral compound 2-*O*-galloylpunicalin (2GP¹³). Here, we report the results of an investigation of the activity of 3 and 41 other bisphosphonates in inhibiting RT-catalyzed AZT excision by ATP. The most active compounds are far more potent than are 3 or pamidronate (4), and we use here a variety of structure-activity relationship methods to relate their structure with function. We also investigate the direct inhibition of RT catalyzed DNA synthesis by these bisphosphonates, finding in most cases that, unlike 2GP, they have little or no activity, an observation of potential importance for their further development as inhibitors of NRTI excision during HIV-1 replication.

2. Results and Discussion

2.1. Structure-activity relationships (SAR)

We investigated 42 bisphosphonates for activity in RT-catalyzed ATP-mediated AZT excision reactions *in vitro*. The structures of 25 compounds (3, 5–28) having activity in the range 0.5–50 μ M are shown (rank ordered in terms of decreasing activity) in Figure 1A and the structures

of 17 additional compounds (**29–45**) having low ($\geq 100 \mu\text{M}$) activity are shown in Figure 1B. The synthesis and characterization of all compounds except **29** and **30** have been reported elsewhere¹⁴ and the samples used here were from the same batches. The synthesis of **29** and **30** were shown in the Experimental Section below, using our previous methods.

We show in Figure 1A the structures of 25 bisphosphonates having high-to-moderate activity in inhibiting RT-catalyzed AZT excision by ATP, ordered in terms of decreasing activity. The IC_{50} values are in the range 500 nM–51.3 μM (Table 1). The structures of a second set of compounds having low activity (IC_{50} values $\geq 100 \mu\text{M}$) are shown in Figure 1B. What is immediately apparent from these results is that none of the conventional, nitrogen containing bisphosphonates, such as incadronate (**35**), zoledronate (**36**) or minodronate (**44**), Figure 1B, used to treat bone-resorption diseases, have appreciable activity in inhibiting AZT-excision, since their IC_{50} values are all $\geq 100 \mu\text{M}$. Several of the other inactive compounds (**31**, **38** and **39**) are also known to be active in inhibiting bone resorption^{15, 16}, and in each case their target is the enzyme farnesyl diphosphate synthase (FPPS). However, targeting FPPS is an undesirable feature for an AZT-excision inhibitor since it is likely to lead to toxicity in host cells.

In the case of the bisphosphonates that are far more active in inhibiting AZT excision, we find a clearly different pattern of sidechain substitution to that seen in the nitrogen containing bisphosphonates. All of the nitrogen-containing bisphosphonates active in bone resorption have a basic nitrogen atom that is protonated when bound to the FPPS enzyme¹⁷, whereas in the case the potent excision inhibitors, the sidechain is expected (based on pK_a values) to be neutral. The four most active compounds have IC_{50} values $\leq 1 \mu\text{M}$ and in each case, these compounds contain halogen substituents on a phenyl or biphenyl ring. In contrast, the two least “active” compounds (**27** and **28**, with IC_{50} values of 38, 51.3 μM , respectively), each contain electron-donating ring substituents. Of all of the active compounds, none were potent inhibitors of RT-catalyzed DNA synthesis, as shown in Figure 2, a desirable feature for an excision inhibitor. We also found that there was little or no activity of these bisphosphonates against the human cell lines tested: IC_{50} values are given in Table 1. For example, **3** had an IC_{50} (averaged over the three cell lines investigated, MCF-7, SF-268, NCI-H460) of $\sim 229 \mu\text{M}$, while the most active species (**5**) had an IC_{50} of $\sim 234 \mu\text{M}$. In contrast, species such as zoledronate and minodronate (**36**, **44**) had IC_{50} values of $\sim 15, 5 \mu\text{M}$, due to potent inhibition of the farnesyl diphosphate synthase enzyme. As expected, **3** and **5** had very weak activity against this target (**44**, 8.5 μM vs 0.14, 0.12 μM for minodronate, zoledronate: data not shown). The presence of both phosphonate groups is critical for activity, as can be seen in the series **5**, **29**, **30**. Both of the latter compounds have P-C (phosphinate) groups, replacing 1 or 2 –OH groups with CH_3 groups, and neither compound has any appreciable activity in inhibiting AZT excision.

2.2. Quantitative structure-activity relationships (QSAR)

We next sought to see to what extent it might be possible to make a more detailed analysis of the activity results shown in Table 1. We first carried out a pharmacophore modeling investigation and obtained the common feature hypothesis shown in Figure 3A. However, this approach did not yield any highly predictive models. We thus next moved to using CoMSIA modeling methods, which, in previous work on bisphosphonate inhibitors^{18–20}, have been shown to be highly predictive. These methods require an alignment of all molecules within a common frame of reference (Figure 3B), which in this case was constructed using the flexible alignment algorithm in the program MOE²¹. We then used the default settings in Sybyl 7.3 to generate steric, hydrophobic, electrostatic, donor and acceptor CoMSIA descriptors at grid points surrounding the alignment. Given the discrete distribution of the RT-enzyme inhibition data, we first investigated the possible utility of a classification approach, rather than regression methods, to analyze the CoMSIA results. For such classification approaches, compound

activity can be assigned using an ordered scale (i.e. active, moderately active, inactive) rather than specific numeric values. The soft independent modeling of class analogy²² (SIMCA) module in Sybyl 7.3 provides one approach with which to create such classification models, based on the CoMSIA fields of the aligned structures. Using this approach we find that the resulting cross-validated model has an overall classification accuracy of 94%, with 100% accuracy among inactive and moderately active groups and 90% accuracy among actives, Figure 4A (see the Supplementary Material, Table S1, for more details).

Given confidence in the results of the classification approach, which can be applied to all of the compounds investigated, we then investigated use of a standard regression method. Due to the limited range of the numeric data, we assigned arbitrarily large (300 μ M) activities to the inactive compounds, in order to increase the range, basically the same approach we used in a previous study²⁰. We then performed a CoMSIA analysis on all compounds, using a partial least squares (PLS) regression approach. The optimal number of components in the final PLS model was determined to be 4 by using q^2 values, as obtained from the SAMPLS²³ leave-one-out cross-validation technique implemented in Sybyl. This four component CoMSIA model ($n=35$) gave $q^2 = 0.63$, $r^2 = 0.91$ and $F = 73$, as shown graphically in Figure 4B (full details shown in Supplementary Material Table S2). Five iterations of a leave-two-out analysis were performed and 10 iterations of activity data randomization were then applied to confirm the predictive ability of the model, and that the final model was not the result of a chance correlation. The hydrophobic, electrostatic and steric fields generated from the model are shown in Figures 3C–E. The (green) favored steric features (Figure 3C) are coincident with the *meta* position of the phenyl ring, while the unfavorable steric feature (yellow, Figure 3C) correlate with the occurrence of *para*-biphenyl substituted and inactive *n*-alkyl species. The (yellow) favored hydrophobic feature (Figure 3E) is basically coincident with the (red) negative charge-favorable field feature (Figure 3D), and can be attributed to the importance of having either a halogen or aromatic ring feature in the *meta* position of the phenyl ring. Experimental and predicted pIC_{50} 's including statistical parameters for the final model are given in Table 2, with training and test set predictions shown graphically in Figure 4B, there being on average a factor of 2x error in the IC_{50} predictions.

We next considered what features might be missing from the CoMSIA fields, or equivalently, why is the dichlorophenyl species **5** so active? One possibility is that these halogenated species might be involved in charge-transfer interactions with an electron-rich amino-acid sidechain in the protein, such as a tyrosine or phenylalanine. Indeed, a TAM mutation found in many HIV-1 mutants and present in our HIV-1 involves T215, and in previous work²⁴ it has been proposed that a major contact between ATP and RT involves aromatic ring stacking interactions between the ATP adenine base and an aromatic ring at position 215²⁴. In the case of a highly electron deficient bisphosphonate sidechain, this interaction could be quite substantial. Of course, in the absence of concrete structural information, we cannot rule out other possibilities, such as a π - π interaction with an electron rich DNA base, although this would probably be expected to have an effect on DNA polymerase activity, which is generally not seen. In either case, however, the presence of halogen substituents in the most potent inhibitors suggests the possibility that π - π or charge transfer interactions might be involved. To test this hypothesis, we computed semi-empirical electron affinities (EA) as well as the *ab initio* vertical electron affinities (VEA) for each of the bisphosphonate sidechains to see: 1) if there was any correlation between electron affinity and excision activity and 2), whether electron affinity might be a useful additional descriptor. The computed EA and VEA values are shown in Table S3 in the Supplementary Material, and we observe good agreement between *ab initio* and semi-empirical calculations, $r^2 = 0.81$, $F = 99$, $p < 0.0001$ (Table S3 and Figure S2, Supplementary Material). When the experimental $pIC_{50} = (-\log_{10} [IC_{50} (M)])$ values for AZT excision by the active compounds are plotted against the EA and VEA values, we obtain the result shown in Figure 4C, in which we see a modest correlation: $r^2 = 0.55$, $F = 28$ and p

< 0.0001 for EA and $r^2 = 0.37$, $F = 14$, $p = 0.0012$ for the VEA. These results are of interest since they suggest that it might be possible to improve upon the CoMSIA results by incorporating the EA or VEA values as additional descriptors. This indeed turns out to be the case (Supplemental Information Tables S4-6) with incorporation of the VEA term resulting in significant improvements in r^2 ($0.91 \rightarrow 0.97$), F ($73 \rightarrow 144$) and the rms error ($0.32 \rightarrow 0.10$). Clearly then, using the CoMSIA and VEA results lead to good activity predictions, and should be of help in the future design of improved excision inhibitors.

The bisphosphonates we have investigated here have IC_{50} values as low as 500nM in AZT excision. This is ~6x higher than that found with 2GP, however, unlike 2GP, the bisphosphonates tested here have essentially no activity on DNA polymerase activity. This is of importance since our purpose is to block, exclusively, AZT excision (not AZT incorporation). We also find that the most potent inhibitors, in general, have IC_{50} values for the inhibition of human cell growth $>250\mu M$, since they do not inhibit the human FPPS (or GGPPS) enzymes, again making them of interest for further development.

3. Conclusion

The results we have presented above are of interest for a number of reasons. First, we have tested a library of 42 bisphosphonates for their ability to inhibit the HIV-1 reverse transcriptase catalyzed phosphorylation of AZT from AZT-terminated primers by ATP. The four most active compounds are all halogen containing aromatic species having IC_{50} values of $\leq 1\mu M$. Second, we have used 3D-QSAR methods to investigate structure-activity relationships. A classification method was found to have an accuracy of 94% in categorizing compounds into three discrete classes: active, moderately active and inactive. In addition, a CoMSIA partial least square regression model was found to yield a predictive model ($q^2 = 0.63$, $r^2 = 0.90$, $F = 73$, $n=35$) for AZT excision. Interpretation of the resulting fields showed a preference for large, hydrophobic/steric substituents at the *meta*- rather than *para*- position of the first ring. Additionally, electron-withdrawing ring substituents (negative charge favored) enhanced activity. Third, we find that there is no significant correlation ($r^2 = 0.10$) between RT-catalyzed AZT excision inhibition and the growth inhibition of three human cell lines, with the most potent excision inhibitors having essentially no activity ($>250\mu M$) in cell growth inhibition. Fourth, we find that there is no inhibition of RT catalyzed DNA synthesis by these potent bisphosphonate excision inhibitors. When taken together, these results strongly support the idea that bisphosphonates may have utility as inhibitors of AZT-excision catalyzed by HIV-1 RT, provided suitable formulations or delivery vehicles are available to facilitate uptake of the charged bisphosphonates into HIV-infectable target cells such as T-lymphocytes. Nonetheless, given the low cytotoxicity of the novel bisphosphonates described in the present work, because they do not target the FPPS enzyme, such compounds are of interest in the context of the future development of novel anti-infectives for HIV-1.

4. Experimental Section

4.1. General

All reagents used were purchased from Aldrich (Milwaukee, WI). The purities of all compounds were routinely monitored by using 1H and ^{31}P NMR spectroscopy at 400 or 500 MHz on Varian (Palo Alto, CA) Unity spectrometers using, in some instances, absolute spin-count quantitative analyses. TLC was performed on silica gel F254 plates (Merck) and UV light (254 nm) and 1% $KMnO_4$ solution were used for visualization.

4.2. Synthesis

The synthesis and characterization of all compounds except **29** and **30** have been reported elsewhere¹⁴ and the samples used here were from the same batches. The synthesis of **29** and **30** were shown below:

4.2.1. 2-(3,4-Dichlorophenyl)ethyl-1,1-bis(methylphosphinic acid) (29)—NaH (44 mg, 1.1 mmol, 60% in oil) was added at 0°C to diethyl methylenebis(methylphosphinate)²⁵ (228 mg, 1 mmol) in dry THF. 3,4-Dichlorobenzyl bromide (240 mg, 1 mmol) was added to the resulting solution and after 1 h, the reaction was quenched with an NH₄Cl solution and extracted with diethyl ether (3 × 20 mL). The organic layer was dried and evaporated and the residue purified using column chromatography (silica gel, ethyl acetate: MeOH/10: 1). The diethyl ester obtained was treated with 3 equiv. of TMSBr in CH₂Cl₂ for 6h. The mixture was then evaporated to dryness, dissolved in water/MeOH, and neutralized to pH ~6. Compound **29** was obtained by filtration as a white powder. ¹H NMR (400 MHz, D₂O): δ 1.21 (d, *J* = 14.4 Hz, 6H, CH₃), 2.3–2.45 (m, 1H, CH), 2.96 (td, *J* = 15.2 Hz, 6.8 Hz, 2H, CH₂), 7.1–7.3 (m, 3H, aromatic); ³¹P NMR (162 MHz, D₂O): δ 47.4; Anal. Calcd for C₁₀H₁₃Cl₂O₄P₂·1.5H₂O·0.6NaBr: C, 27.19; H, 3.65. Found: C, 27.14; H, 3.47.

4.2.2. 2-(3,4-Dichlorophenyl)-1-(methylphosphino) ethylphosphonic acid (30)—NaH (44 mg, 1.1 mmol, 60% in oil) was added at 0°C to triethyl methylphosphinomethylenephosphonate²⁶ (258 mg, 1 mmol) in dry THF. 3,4-Dichlorobenzyl bromide (240 mg, 1 mmol) was added to the resulting solution and after 1 h, the reaction was quenched with an NH₄Cl solution and extracted with diethyl ether (3 × 20 mL). The organic layer was dried and evaporated and the residue purified using column chromatography (silica gel, ethyl acetate: MeOH/10: 1). The diethyl ester obtained was treated with 4.5 equiv. of TMSBr in CH₂Cl₂ for 6h. The mixture was then evaporated to dryness, dissolved in water/MeOH, and evaporated again to give compound **30** as a white powder. ¹H NMR (400 MHz, D₂O): δ 1.23 (d, *J* = 14.4 Hz, 3H, CH₃), 2.2–2.35 (m, 1H, CH), 2.85–3.05 (m, 2H, CH₂), 7.1–7.3 (m, 3H, aromatic); ³¹P NMR (162 MHz, D₂O): δ 18.3 (s, 1P), 49.6 (s, 1P). Anal. Calcd for C₉H₁₂Cl₂O₅P₂: C, 26.75; H, 3.24. Found: C, 26.90; H, 3.00.

4.3. Biological activity testing

4.3.1. Protein Expression—TAM-RT with the mutations D67N/K70R/T215F/K219Q was expressed and purified as previously described²⁷. The protein concentration of the purified enzyme was determined by spectrophotometry at 280 nm using an extinction coefficient of 260,450 M⁻¹ cm⁻¹. [³H]-TTP and [γ-³²P]-ATP were products of PerkinElmer Life Sciences (Boston, MA). The homopolymeric template-primer (T/P) poly(rA)-oligo(dT)_{12–18} used for steady state kinetic studies was obtained from GE Healthcare (Piscataway NJ). AZTTP as well as DNA oligonucleotides used to prepare the heteropolymeric T/P for excision assays were obtained from Trilink Biotechnologies (San Diego, CA).

4.3.2. Steady-state analysis of bisphosphonate inhibition of RT DNA polymerase activity—TAM-RT RNA-dependent DNA polymerase activity in the absence or presence of varying concentrations of bisphosphonate inhibitor was determined using 0.2 units/mL of poly(rA)-oligo(dT)_{12–18}, 2 nM RT, 5 μM [³H] TTP in a final volume of 50 μL of 50 mM Tris-HCl, pH 8.0 containing 60 mM KCl and 10 mM MgCl₂. Samples were incubated for 20 min at 37 °C and then quenched by adding 200 μL of ice-cold 10% trichloroacetic acid containing 20 mM sodium pyrophosphate. After a 20 minute incubation on ice, samples were filtered through 1.2 μm glass fiber type-C filters in 96-well microplates (Millipore, Bedford MA). The filters were washed sequentially with 10% TCA and ethanol, and the extent of [³H]-TMP incorporation into the precipitated nucleic acid was quantified by liquid scintillation spectrometry.

4.3.3. Assay of RT-catalyzed ATP-mediated phosphorolysis of chain-terminating AZT—

In vitro ATP-dependent AZTMP excision reactions were carried out using a direct assay, essentially as previously described (4). Briefly, a 19-nt DNA primer (3'-CAG GGG GGA AAA GAA AAT T -5') was annealed to a 57-nt DNA template (5'-CGT TGT CAG TGA ATC AGC CCT TCC AGT CCC CCC TTT TCT TTT AAA AAG TGG CTA AGA-3') to prepare the heteropolymeric template/primer (T/P). The 19 nt DNA primer was 5'-radiolabeled with [γ - 32 P]-ATP and T4 polynucleotide kinase (New England BioLabs, Ipswich, MA) according to the manufacturer's instructions. The labeled primer was purified using denaturing polyacrylamide gel electrophoresis on 7M urea-16% polyacrylamide gels, followed by elution from the gel. The purified 5'- 32 P-labeled primer was then annealed to the 57 nt DNA template using a 1:1.2 molar ratio of template to primer, by heating to 90°C followed by slow cooling to ambient temperature to form the 57 nt/19 nt template-primer (57/19 T/P) substrate. AZTMP was added to the primer 3'-terminus of the 57 nt/5'-[32 P]-19 nt T/P by incubating with wt RT and 100 μ M AZTTP for 30 min at 37°C. The resulting [32 P]-labeled, chain-terminated 20 nt primer was purified by elution of the appropriate band following electrophoretic resolution on 7M urea-16% acrylamide denaturing gels. The purified chain-terminated primer was then re-annealed to the 57 nt DNA template DNA primer and stored at -20°C for use as T/P in the phosphorolysis experiments.

The phosphorolytic removal of chain-terminating 3'-AZTMP in the absence or the presence of varying concentrations of bisphosphonates was assayed by incubating TAM-RT with the AZTMP-terminated T/P (4:1 ratio of RT:T/P) in 50 mM Tris-HCl pH 8.0, 50 mM KCl. Reactions were initiated by addition of 10 mM MgCl₂ and 3.0 mM ATP. Inorganic pyrophosphatase (0.01 U; Sigma) was included in phosphorolysis reactions using ATP, to ensure removal of any contaminating PPi in the ATP preparation. Aliquots were removed at defined times and quenched with an equal volume of gel loading dye (98% deionized formamide, 10 mM EDTA and 1 mg/mL each of bromophenol blue and xylene cyanol). The 20 nt 3'-AZTMP terminated substrate and 19 nt excision products were separated by denaturing gel electrophoresis and quantified by phosphorimaging.

4.3.4. Human Cell Growth Inhibition Assay—Human tumor cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (lung large cell), and SF-268 (central nervous system glioblastoma) were obtained from the National Cancer Institute and maintained at 100% humidity and 5% CO₂ at 37°C. Cell lines were cultured in RPMI-1640 medium supplemented with 2mM L-glutamine and 10% fetal bovine serum (Gibco, Grand Island, NY) at 37°C in a 5% CO₂ atmosphere with 100% humidity. 0.01 M compound stock solutions were prepared in water or DMSO. A broth microdilution method was used to determine bisphosphonate growth inhibition IC₅₀ values. Compounds were half-log serial diluted from 316 μ M - 10nM into 96-well TC-treated flat bottom plates (Corning Inc., Corning, NY) using cell culture media. In cases where DMSO was used, the range of dilution was 100 μ M - 10nM. Cells were plated at a density of 5,000 cells/well and contained 10 μ L of the compound of interest in a final volume of 100 μ L. Cells were then incubated for 4 days, at which time an MTT ((3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) was performed, in order to obtain growth inhibition dose response curves. Briefly, cells were incubated for 2 hours with the tetrazolium salt, lysed with detergent and incubated O/N, protected from light and at room temperature. The absorbance at 600nm was read the following day using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). The compound concentrations for 50% growth inhibition (IC₅₀ values) were

obtained by fitting the absorbance data to a rectangular hyperbolic function: $I = \frac{(I_{\max})(C)}{IC_{50} + C}$, where I is the percent inhibition, I_{max} = 100% inhibition and C is the concentration of the inhibitor, using GraphPad PRISM 3.0 software for Windows (Graphpad Software Inc., San Diego, CA).

4.3.5. FPPS Inhibition—Human FPPS was expressed and purified as described previously²⁸. Human FPPS assays were carried out using 96 well plates with a 200 μ L reaction mixture in each well. The condensation of geranyl diphosphate with isopentenyl diphosphate was monitored by a continuous spectrophotometric assay for phosphate releasing enzymes²⁹. The reaction buffer contained 50 mM Tris-HCl, 1 mM $MgCl_2$, at pH 7.4. The compounds investigated were pre-incubated with the enzyme for 30 minutes at 20°C. The IC_{50} values were obtained by fitting the inhibition data to a normal dose-response curve using Origin 6.1 (OriginLab Corporation, Northampton, MA).

4.4. Computational Methods

4.4.1. Pharmacophore Model—A common feature pharmacophore was constructed in MOE²¹ using the consensus pharmacophore module and the polarity-charge-hydrophobicity (PCH) scheme. The pharmacophore was perceived from energy minimized structures of the most active compounds using tolerances of 1.2 and a threshold of 25%. The final model was simplified by combining the features of each individual P-O group into two master functions, each describing the phosphonate group as an anionic metal ligator. Tolerances (sphere sizes) encompassing each feature were enlarged uniformly in order to relax the mapping requirements.

4.4.2. SIMCA analysis—To carry out classification analysis we used the Soft Independent Modeling of Class Analogy²² (SIMCA) module in Sybyl 7.3. The dataset was divided into three classes: active ($IC_{50} < 10 \mu M$), moderately active ($10-100 \mu M$), and inactive ($IC_{50} > 100 \mu M$). SIMCA analysis was then performed by using the assigned classes and CoMSIA fields (see below), with default settings (CoMFA standard scaling and column filtering at 2.0 kcal/mol). Models were automatically cross-validated by the algorithm, with classification rates, sum of squared residuals and other details being reported.

4.4.3. CoMSIA Alignment—To carry out our comparative molecular similarity indices analysis (CoMSIA)³⁰ calculations, we began by building and geometry optimizing the bisphosphonate structures in the Molecular Operating Environment program (MOE)²¹. Minimized structures were generated using the MMFF94x forcefield³¹ and default minimization parameters, which apply three successive non-linear optimization methods: steepest descent, conjugate gradient and truncated-Newton. Minimized structures were then manually aligned to the lowest energy conformation of the most active compound (**5**). The manual alignment was subsequently refined using the flexible alignment module in MOE, which perceives common features between molecules (e.g. aromaticity and volume) and attempts to improve the alignment of such features. The aligned compounds were then exported to Sybyl 7.3³² for analysis: all CoMSIA fields were computed on a rectangular grid, using default grid spacing and probe atoms.

4.4.4. Quantum Chemical Calculations—Vertical electron affinities (VEA) were calculated for the sidechains of aromatic bisphosphonates using the Gaussian 03 program³³ following an approach described previously.³⁴ Basically, compounds were geometry optimized using the B3LYP functional and a 6-31G* basis set, and a frequency calculation was used to confirm that the geometries did not represent saddle points. Single point energy calculations were then carried out for the neutral, optimized geometries, using B3LYP, a 6-311+G(2df,p) basis set with tight convergence, no symmetry constraints, and an ultrafine grid. UB3LYP was used to calculate the single point energy structures, after adding an additional electron, again using the 6-311+G(2df,p) basis set and the options specified for the neutral molecules. The stability of the wavefunction for the charged species was verified with the Stable=Opt keyword. The VEA was taken to be the difference between the total eigen-energies of the neutral and charged species. For purposes of comparison, sidechain electron affinities

were also computed semi-empirically within Maestro using the PM3 Hamiltonian³⁵. Structures of the sidechains were prepared using LigPrep³⁶ with default options. Electron affinities (EA) were computed using QikProp³⁷ specifying full, rather than fast mode.

Acknowledgments

This work was supported by the United States Public Health Service (NIH grants AI-060452 and AI-052010 to M.A.P., GM-073216 to E.O.). Y.S. was supported by a Leukemia and Lymphoma Society Special Fellowship. J.M.W.C. was a Jean Dreyfus Boissevain Fellow.

References

1. UNAIDS/WHO AIDS Epidemic Update. United Nations Programme on HIV/AIDS; December, 2006.
2. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. Proc Natl Acad Sci U S A 1985;82:7096. [PubMed: 2413459]
3. Meyer PR, Matsuura SE, So AG, Scott WA. Proc Natl Acad Sci U S A 1998;95:13471. [PubMed: 9811824]
4. Dharmasena S, Pongracz Z, Arnold E, Sarafianos SG, Parniak MA. Biochemistry 2007;46:828. [PubMed: 17223704]
5. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. Mol Cell 1999;4:35. [PubMed: 10445025]
6. Larder BA, Kemp SD. Science 1989;246:1155. [PubMed: 2479983]
7. Kellam P, Boucher CA, Larder BA. Proc Natl Acad Sci U S A 1992;89:1934. [PubMed: 1371886]
8. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A, Larder BA. J Virol 1996;70:5930. [PubMed: 8709214]
9. Hooker DJ, Tachedjian G, Solomon AE, Gurusinge AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ. J Virol 1996;70:8010. [PubMed: 8892925]
10. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. J Virol 1998;72:5093. [PubMed: 9573280]
11. Parniak, MA.; McBurney, S.; Oldfield, E.; Mellors, JW. Antiviral Therapy. Tenerife Sur-Costa Adeje; Canary Islands, Spain: 2004. Bisphosphonate inhibitors of nucleoside reverse transcriptase inhibitor excision.
12. Cruchaga C, Anso E, Rouzaut A, Martinez-Irujo JJ. J Biol Chem 2006;281:27744. [PubMed: 16829515]
13. Cruchaga CAE, Font M, Martino VS, Rouzaut A, Martinez-Irujo JJ. Biochem J 2007;405:165. [PubMed: 17355225]
14. Kotsikorou E, Song Y, Chan JM, Faelens S, Tovian Z, Broderick E, Bakalara N, Docampo R, Oldfield E. J Med Chem 2005;48:6128. [PubMed: 16162013]
15. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Bone 1987;8(Suppl 1):S35. [PubMed: 2825741]
16. Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramseier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR. J Med Chem 2002;45:3721. [PubMed: 12166945]
17. Mao J, Mukherjee S, Zhang Y, Cao R, Sanders JM, Song Y, Zhang Y, Meints GA, Gao YG, Mukkamala D, Hudock MP, Oldfield E. J Am Chem Soc 2006;128:14485. [PubMed: 17090032]
18. Sanders JM, Gomez AO, Mao J, Meints GA, Van Brussel EM, Burzynska A, Kafarski P, Gonzalez-Pacanowska D, Oldfield E. J Med Chem 2003;46:5171. [PubMed: 14613320]
19. Sanders JM, Song Y, Chan JM, Zhang Y, Jennings S, Kosztowski T, Odeh S, Flessner R, Schwerdtfeger C, Kotsikorou E, Meints GA, Gomez AO, Gonzalez-Pacanowska D, Raker AM, Wang H, van Beek ER, Papapoulos SE, Morita CT, Oldfield E. J Med Chem 2005;48:2957. [PubMed: 15828834]
20. Hudock MP, Sanz-Rodriguez CE, Song Y, Chan JM, Zhang Y, Odeh S, Kosztowski T, Leon-Rossell A, Concepcion JL, Yardley V, Croft SL, Urbina JA, Oldfield E. J Med Chem 2006;49:215. [PubMed: 16392806]

21. MOE. Chemical Computing Group, Inc; Montreal, Quebec: 2006. 2006.08
22. Wold, S.; Sjostrom, M. Chemometrics: theory and application. American Chemical Society; 1977.
23. Bush BL, Nachbar RB. J Comput Aided Mol Des 1993;7:587. [PubMed: 8294948]
24. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. J Virol 2001;75:4832. [PubMed: 11312355]
25. Prishchenko AA, Novikova ZS, Lutsenko IF. Zhurnal Obshchei Khimii 1977;47:2689.
26. Teulade MP, Savignac P, Aboujaoude EE, Collignon N. J Organomet Chem 1986;312:283.
27. Fletcher RS, Holleschak G, Nagy E, Arion D, Borkow G, Gu Z, Wainberg MA, Parniak MA. Protein Expr Purif 1996;7:27. [PubMed: 9172779]
28. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U. Proc Natl Acad Sci U S A 2006;103:7829. [PubMed: 16684881]
29. Webb MR. Proc Natl Acad Sci U S A 1992;89:4884. [PubMed: 1534409]
30. Klebe G, Abraham U, Mietzner T. J Med Chem 1994;37:4130. [PubMed: 7990113]
31. Halgren TA. J Comput Chem 1996;17:490.
32. Sybyl 7.3. Tripos Inc; St. Louis: 2006.
33. Frisch, MJ.; Trucks, GW.; Schlegel, HB.; Scuseria, GE., et al. Gaussian, Inc; Wallingford, CT: 2004.
34. Mariano D, Vera A, Pierini AB. Phys Chem Chem Phys 2004;6:2899.
35. Maestro 8.0. Schrodinger Inc; Portland, OR:
36. LigPrep 2.1. Schrodinger Inc; Portland, OR:
37. QikProp 3.0. Schrodinger Inc; Portland, OR:

Figure 1.

Structures of bisphosphonate inhibitors. **A**, 25 active species investigated, rank ordered by decreasing activity. **B**, Additional, inactive species ($IC_{50} \geq 100 \mu M$).

Figure 2. Inhibition of RT catalyzed ATP-mediated phosphorolysis (green) and DNA synthesis (orange) at 5 μ M inhibitor. Foscarnet, used as a control.

Figure 3.

Structure-activity schematics. **A**, Common feature pharmacophore: Yellow spheres, combined feature of acceptor and metal ligator representing a phosphonate group; purple sphere, donor or hydrophobic; green sphere, aromatic; cyan sphere, aromatic or hydrophobic. **B–E**, CoMSIA alignment and results; **B**, Flexible common feature alignment used for CoMSIA, showing heavy atoms only; **C**, Steric fields; green favored, yellow disfavored; **D**, Electrostatic fields; blue positive charge favored, red, positive charge-disfavored; **E**, Hydrophobic fields; yellow favorable, grey disfavored.

Figure 4.

CoMSIA modeling results; **A**, SIMCA results, the overall classification accuracy is 94%.

Actual and predicted classes shown, yellow box indicating classification error; **B**, PLS

regression results, $q^2 = 0.63$, $r^2 = 0.90$, $F = 73$, $n = 35$. Test and training set results shown:

training = ●, test = ○; **C**, Activity-electron affinity correlations. ● = EA, $r^2 = 0.55$, $F = 28$; ▼ =

VEA, $r^2 = 0.37$, $F = 14$.

Table 1

Inhibition of ATP-mediated AZT excision from HIV-1 reverse transcriptase

Compound ^a	Excision Inhibition IC ₅₀ (μM)	MCF-7 IC ₅₀ (μM)	SF-268 IC ₅₀ (μM)	NCI-H460 IC ₅₀ (μM)
5	0.5	213	208	241
6	0.9	41	48	39
7	1.0	>300	>300	>300
8	1.0	225	236	253
9	1.3	259	225	248
10	1.5	165	122	141
11	1.9	173	224	175
12	2.1	>300	>300	>300
13	2.2	>100 ^b	>100 ^b	>100 ^b
14	2.4	128	139	118
15	2.9	>300	>300	>300
3	3.2	289	269	253
16	3.3	188	176	212
17	3.5	>100 ^b	>100 ^b	>100 ^b
18	3.9	>100 ^b	>100 ^b	>100 ^b
19	3.9	>300	>300	>300
20	4.6	84 ^b	95 ^b	95 ^b
21	5.0	296	297	301
22	5.2	n.d.	n.d.	n.d.
23	5.4	>300	>300	>300
24	7.9	>300	>300	>300
25	9.5	>300	>300	>300
26	11.2	>300	>300	>300
27	38.0	205	186	187
28	51.3	>300	>300	>300

^a Structures shown in Figure 1.^b Compounds dissolved in dimethyl sulfoxide (DMSO)

Table 2
CoMSIA Results for inhibition of AZT excision by bisphosphonates

Compound ^a	Experimental		CoMSIA pIC ₅₀ Predictions							
	IC ₅₀ (μM)	pIC ₅₀ (M)	Training Set	Test Sets ^b					Pred	Residual
				1	2	3	4	5		
5	0.5	6.3	6.1	6.1	6.1	6.1	6.2	6.1	6.1	0.2
6	0.9	6.1	5.9	5.9	5.9	5.8	5.9	5.9	5.8	0.2
7	1.0	6.0	5.6	5.8	5.8	5.8	5.8	5.8	5.8	0.2
8	1.0	6.0	5.9	5.8	5.8	5.8	5.9	5.8	5.8	0.1
9	1.3	5.9	5.9	5.8	5.8	5.7	5.8	5.6	5.6	0.3
10	1.5	5.8	5.9	5.9	5.8	5.8	5.8	5.8	5.8	0.0
11	1.9	5.7	5.9	5.8	5.7	5.7	5.8	5.7	5.8	0.0
12	2.1	5.7	5.5	5.6	5.5	5.6	5.6	5.6	5.5	0.1
13	2.2	5.7	5.5	5.7	5.7	5.7	5.6	5.7	5.7	0.0
14	2.4	5.6	5.8	5.6	5.6	5.6	5.9	5.6	5.9	-0.3
15	2.9	5.5	5.4	5.4	5.4	5.5	5.7	5.5	5.5	0.0
3	3.2	5.5	5.5	5.7	5.7	5.6	5.6	5.6	5.7	-0.2
16	3.3	5.5	5.6	5.5	5.6	5.6	5.6	5.6	5.6	-0.1
17	3.5	5.5	5.0	5.1	5.1	5.2	5.2	5.2	5.2	0.3
18	3.9	5.4	5.4	5.5	5.4	5.4	5.4	5.4	5.4	0.0
19	3.9	5.4	5.2	5.2	5.2	5.2	5.5	5.2	5.2	0.2
20	4.6	5.3	4.7	4.4	5.5	5.3	5.3	5.3	4.4	0.9
21	5.0	5.3	5.5	5.6	5.6	5.5	5.5	5.5	5.5	-0.2
22	5.2	5.3	5.8	5.8	5.8	5.8	5.8	5.8	5.8	-0.5
23	5.4	5.3	5.4	5.3	5.2	5.1	5.2	5.2	5.1	0.2
24	7.9	5.1	4.9	5.1	5.1	5.1	5.1	5.0	5.1	0.0
25	9.5	5.0	4.9	5.0	5.0	5.0	4.9	4.7	4.7	0.3
26	11	5.0	5.0	4.8	5.8	5.2	5.1	5.2	5.8	-0.9
27	38	4.4	4.4	4.2	4.2	4.2	4.2	4.2	4.2	0.2
28	51	4.3	4.9	4.4	4.6	4.5	4.5	4.5	4.5	-0.2

CoMSIA pIC ₅₀ Predictions										
Experimental			Test Sets ^b							
Compound ^a	IC ₅₀ (μM)	pIC ₅₀ (M)	Training Set	1	2	3	4	5	Pred	Residual
38	302	3.5	3.1	3.3	3.3	3.3	3.4	3.3	3.3	0.2
41	302	3.5	3.9	3.5	3.5	3.5	3.6	3.5	3.5	0.0
42	302	3.5	3.7	3.3	3.3	3.3	3.4	3.3	3.3	0.2
40	302	3.5	4.2	4.1	4.0	4.1	4.1	4.0	4.1	-0.5
33	302	3.5	3.2	3.4	3.3	3.3	3.2	3.3	3.3	0.2
43	302	3.5	3.9	3.9	3.9	3.9	3.9	3.9	3.9	-0.4
34	302	3.5	3.6	3.6	3.6	3.7	3.6	3.6	3.6	-0.1
31	302	3.5	3.3	3.6	3.6	3.6	3.6	3.6	3.6	-0.1
45	302	3.5	3.4	3.7	3.6	3.6	3.4	3.6	3.6	0.0
		q ²	0.63	0.70	0.68	0.66	0.67	0.61		
		r ²	0.91	0.96	0.95	0.95	0.97	0.95		
		F test	73	115	108	107	151	110		
		N	35	33	33	33	33	33		
		n	4	5	5	5	5	5		
		% Steric	0.19	0.19	0.19	0.19	0.18	0.18		
		% Electrostatic	0.32	0.33	0.35	0.35	0.34	0.35		
		% Hydrophobic	0.28	0.27	0.27	0.27	0.29	0.27		
		% Donor	0.20	0.20	0.20	0.20	0.21	0.20		

^a Structures shown in Figure 1.

^b Bold values represent predicted activities of compounds that were not included in the training set.